Mereo BioPharma (MREO) FCF Margin (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly FCF Margin of 1530.2% for Q2 2025, down 125.39% quarter-over-quarter from 678.9% in Q4 2023.
Mereo BioPharma (MREO) FCF Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported FCF Margin for 2 consecutive years, with 1530.2% the latest figure, recorded in Q2 2025.
- In Q2 2025, FCF Margin changed N/A year-over-year to 1530.2%; the TTM figure through Dec 2025 stood at 6198.2% (changed N/A YoY), while the FY2025 annual figure was 6198.2%, changed N/A from the prior year.
- FCF Margin declined to 1530.2% in Q2 2025 per MREO's latest filing, from 678.9% in the prior quarter.
- Across five years, FCF Margin topped out at 678.9% in Q4 2023 and bottomed at 1530.2% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 70.82% |
| 10 | Mereo BioPharma | 47.43 Mn | 47.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1,530.20% |
| Dec 31, 2023 | -678.90% |